CION Ameerpet
Pancreatic Cancer · Neuroendocrine Tumours (PNET) · Reviewed by CION Oncologists
PRRT for pancreatic neuroendocrine tumours — who it suits, and how it is arranged
PRRT is a receptor-targeted radiation treatment given into a vein, not aimed from outside the body. It is a real option for some pancreatic neuroendocrine tumours and the wrong treatment for others — and a scan, not an opinion, decides which. This page explains what it is, who it is considered for, and which parts CION delivers versus coordinates with partner centres.
- Receptor-targeted, not external beam — the radiation is carried to the tumour by a peptide that binds a receptor on its cells.
- A receptor scan decides eligibility — if the tumour does not take up the tracer, PRRT has nothing to bind to.
- Coordinated, not in-house — PRRT and DOTATATE PET-CT happen at partner centres and may be billed there.
- Everything around it stays with us — assessment, systemic therapy, scans, nutrition and follow-up, across 35+ centres.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What PRRT Actually Is, in Plain Terms
Nearly every PRRT pancreatic neuroendocrine enquiry that reaches us begins the same way. Someone has read that there is a radiation treatment aimed specifically at these tumours, and wants to know whether it applies to them. PRRT stands for peptide receptor radionuclide therapy, and the short answer is that it is a real, established option for a particular group of people with a pancreatic neuroendocrine tumour — and the wrong treatment for others who have one.
The idea behind it is simpler than the name suggests. Many well-differentiated neuroendocrine tumours carry a large number of somatostatin receptors on the surface of their cells. A small peptide can be built to lock onto that receptor. Attach a radioactive atom to that peptide, put it into a vein, and the radiation is carried by the bloodstream to wherever those receptors are — the tumour in the pancreas, and any deposits elsewhere — rather than being aimed from outside the body at one place. That is the whole principle: the tumour is treated because of what its cells express, not because of where they happen to sit.
This makes PRRT quite different from the external-beam radiation most people picture. There is no daily trip to a machine. It is given as an infusion, a small fixed number of times, some weeks apart, at a nuclear medicine unit licensed to handle radioactive material. Between treatments you are at home, following straightforward radiation-safety instructions for a short period after each one.
Because everything rests on the receptor genuinely being present, the gatekeeper is a scan rather than an opinion. DOTATATE PET-CT for neuroendocrine tumours uses a tracer that binds the same receptor, so a tumour that lights up brightly is telling you the target is there, and one that does not is telling you PRRT would have nothing to attach to. Where PRRT then sits in the running order, and what usually comes before it, is covered in how pancreatic neuroendocrine tumours are treated. One thing to be clear about from the outset: at CION both the receptor scan and PRRT itself are coordinated with partner nuclear medicine centres and may be billed there. We arrange them, read them and build the plan around them; we do not deliver them under our own roof.
Did you know? The NCCN Guidelines for Neuroendocrine and Adrenal Tumors include peptide receptor radionuclide therapy among the systemic options for somatostatin-receptor-positive, well-differentiated neuroendocrine tumours that are advanced or progressing, and they make somatostatin-receptor imaging the test that establishes whether that receptor target is actually present before the therapy is considered at all. The WHO classification draws the line the whole approach depends on: well-differentiated neuroendocrine tumours, sorted by grade according to how quickly the cells are dividing, sit on one side; poorly differentiated neuroendocrine carcinoma sits on the other, where receptor expression is usually lost and PRRT is not the relevant treatment. Which side of that line your pathology report places you on matters far more than the word “neuroendocrine” on its own.
Eligibility, honestly
Who PRRT Is Actually Considered For
These are the things a specialist weighs before PRRT is even raised as a possibility. Most of them can be answered from a pathology report and a scan.
Receptor status
The tumour has to light up
Uptake on a somatostatin-receptor scan is the one non-negotiable requirement. No meaningful uptake means there is no target for the treatment to bind to, whatever else the reports say.
Tumour type
Well differentiated, not poorly differentiated
PRRT belongs to the well-differentiated neuroendocrine tumour side of the WHO classification. Poorly differentiated neuroendocrine carcinoma is a different disease and is treated differently.
Disease state
Advanced, or clearly progressing
It is generally considered where disease cannot be removed by an operation, or where it has grown despite earlier treatment — not for a small tumour a surgeon could take out.
Sequence
Usually not the first move
Somatostatin-analogue-class therapy commonly comes first for receptor-positive tumours. PRRT is more often the step considered when that is no longer holding the disease.
Organ function
Kidneys and bone marrow have to be up to it
The kidneys clear the dose from the body and the marrow feels the effect, so counts and kidney function are checked before each treatment and are a genuine limiting factor.
Practicalities
Travel, timing and radiation safety
Each infusion means travelling to a licensed nuclear medicine unit and keeping some distance from young children for a short period afterwards. Worth planning before you agree to it.
Take this to your appointment
Questions Worth Asking Before You Agree to PRRT
Written down, in the order they are most useful. None of them is a difficult question to ask, and each one changes the answer you get.
- Does my tumour actually take up the tracer, and how strongly? Ask for the receptor scan finding in words, not only the conclusion line. What a DOTATATE PET-CT shows explains what is being judged.
- Is my tumour well differentiated, and what grade is it? Both sit on the pathology report. Together they decide whether PRRT is even the right family of treatment for you.
- What have we tried already, and has it stopped working? PRRT is usually considered after receptor-directed systemic therapy rather than instead of it. The full PNET treatment sequence sets out the usual order.
- What are we hoping this achieves? Control of growth, relief of hormone symptoms, shrinkage before an operation, or something else. Ask for the goal in plain words before anything is booked.
- Where would it be given, and who bills for it? PRRT is delivered at a partner nuclear medicine centre, so the referral, the dates and that part of the cost sit outside CION. Ask for the split in writing.
- What happens if it is not suitable? A receptor-negative scan closes one door and opens others. Pancreatic cancer treatment in Hyderabad covers the systemic and radiation options that remain, and the complete pancreatic cancer guide gives the wider picture.
If you have been told PRRT might be an option and nobody has explained what would have to be true for that to happen, bring the pathology report and the scan discs in. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
PRRT Is One Option, Not the Whole Plan
Knowing where it sits in the sequence is far more useful than knowing that it exists.
Be clear about this
What CION Does In-House, and What Is Coordinated
A PRRT pathway is delivered by more than one team. This is the honest split, so you know who to call and where each part of the bill sits.
| Part of your care | Where it happens | What that means for you |
|---|---|---|
| The first assessment and the decision on whether PRRT is worth pursuing | In-house at CION | A free 45-minute consultation, then tumour-board review, across 35+ centres in Telangana and Andhra Pradesh. |
| Pathology review — tumour type, differentiation and grade | In-house at CION | We read the report with you and say plainly whether it puts you on the side of the line where PRRT is even relevant. |
| Imaging and bloods — pancreatic-protocol CT, MRI/MRCP, chromogranin, CA 19-9 where relevant, kidney function and counts | In-house at CION | Ordered, performed and reported by us, before treatment and between courses. |
| DOTATATE PET-CT to confirm receptor status | Coordinated with partner nuclear medicine and imaging centres | Arranged and scheduled by us, performed at a partner unit, and may be billed there. |
| PRRT itself — the infusions and the radiation-safety period around them | Coordinated with partner nuclear medicine centres | Delivered by the partner unit under its own radiation licence. That part of the cost sits with them, not with us. |
| Systemic therapy for PNETs, including somatostatin-analogue-class treatment | In-house at CION | Given and monitored by our medical oncology team, before PRRT and often continuing alongside it. |
| Radiation, chemoradiation and SBRT where they form part of the plan | In-house at CION | Planned and delivered by our radiation oncology team. |
| EUS-FNA biopsy, ERCP and biliary or duodenal stenting | Coordinated with gastroenterology and endoscopy partners | Arranged and scheduled by us, performed at a partner unit, and may be billed there. |
| Any pancreatic operation for a neuroendocrine tumour | Coordinated with specialist HPB / GI surgeons | Performed by partner surgeons at their hospital, with that part of the cost sitting with them. |
| Nutrition, enzyme (PERT) support, pain, psycho-oncology and survivorship follow-up | In-house at CION | Available before treatment starts, and for as long as you need it afterwards. |
The non-radionuclide arms of the plan — systemic therapy, radiation where it applies, nutrition and follow-up — are set out in pancreatic cancer treatment in Hyderabad.
Your first appointment
How a PRRT Referral Is Actually Arranged
From the first consultation to the point where dates are offered. Most of this is answering a question, not starting a treatment.
-
A free 45-minute consultation
Long enough to read the pathology report and the scans with you, hear how the disease has behaved so far, and say plainly whether PRRT is a realistic question for your situation or a distraction from it.
In-house at CION -
The pathology report is read properly
Well differentiated or poorly differentiated, the grade, and what has already been given. Most PRRT questions are actually settled here, before any new scan is ordered.
In-house at CION -
Receptor imaging is arranged
If the question is still open, we book and schedule the DOTATATE PET-CT at a partner nuclear medicine centre and bring the images back for review. That scan may be billed there.
Coordinated with partner centres -
The board decides where PRRT sits in the sequence
Medical, surgical and radiation oncologists look at the receptor scan, the grade and the pattern of growth together, and place PRRT in an order alongside the other PNET treatments rather than in isolation.
In-house at CION -
The referral, the dates and the cost split
A written estimate with an explicit split between what CION bills and what the partner centre bills, whether Aarogyasri, NTR Vaidya Seva or your own insurance applies to each part, and who to call between treatments.
In-house at CION
No rushed decisions and no unnecessary scans. If PRRT is not the right answer for you, we will say so and explain exactly why. Book a free consultation or call 1800 202 8726.
Take the next step
A Straight Answer on Whether PRRT Applies to You
One team reads the report, arranges the receptor scan and holds the plan around it. We walk this journey with you.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
PRRT for pancreatic neuroendocrine tumours — your questions answered
What is PRRT for neuroendocrine tumours?
PRRT stands for peptide receptor radionuclide therapy. Many well-differentiated neuroendocrine tumours carry large numbers of somatostatin receptors on their cell surface. PRRT uses a small peptide built to lock onto that receptor, with a radioactive atom attached to it. Given as an infusion into a vein, it travels in the bloodstream and delivers its radiation wherever those receptors are, including deposits outside the pancreas, rather than being aimed from outside the body at a single site. It is given a small fixed number of times, some weeks apart, at a licensed nuclear medicine unit. Because the whole approach depends on the receptor genuinely being present, a somatostatin-receptor scan is done first and effectively decides whether the treatment is possible at all.
Does CION give PRRT, or is it arranged somewhere else?
It is arranged somewhere else, and we would rather say that plainly than have you find out later. PRRT is delivered at partner nuclear medicine centres that hold their own licence to handle radioactive material, and the DOTATATE PET-CT that establishes eligibility is performed at a partner imaging unit. Both are coordinated by us and may be billed there. What CION delivers directly is everything around them: the first assessment, the pathology review, the tumour-board decision on whether PRRT belongs in your plan, systemic therapy for neuroendocrine tumours, imaging and blood monitoring, nutrition and enzyme support, and long-term follow-up. You get one team holding the plan, and a written split of who bills for what before anything is booked.
How will I know whether PRRT would even work for my tumour?
Two documents answer most of it. The first is your pathology report, which says whether the tumour is well differentiated and gives its grade. PRRT belongs to the well-differentiated side of the WHO classification; poorly differentiated neuroendocrine carcinoma is a different disease that is treated differently. The second is a somatostatin-receptor scan, usually a DOTATATE PET-CT. If the tumour takes up the tracer strongly, the target the treatment relies on is present. If it does not, PRRT has nothing to bind to and would not help you, however advanced the disease is. Kidney function and blood counts are checked as well, because they set a practical limit on whether a course can be given safely.
What does having PRRT involve, and what are the side effects?
Each treatment is an infusion given over a few hours at a nuclear medicine unit, with a separate infusion running alongside it to protect the kidneys. You usually stay for a short period afterwards while radiation levels fall, then go home with clear instructions about keeping some distance from young children and pregnant family members for a few days. Nausea during and shortly after the infusion is common and is treated. Tiredness tends to build over the course rather than arrive suddenly. Blood counts often dip in the weeks after each treatment, which is why they are checked before the next one, and kidney function is monitored for longer. Most people carry on with ordinary life in between. Your own risks depend on your kidneys, your counts and what treatment you have had before.
Is PRRT a cure for a pancreatic neuroendocrine tumour?
It is honest to say that PRRT is generally given to control disease rather than to remove it. For receptor-positive tumours that are advanced or growing despite earlier treatment, it can shrink deposits, slow growth, ease hormone-related symptoms and buy meaningful time with reasonable quality of life. In some situations shrinkage changes what is possible next. What it is not is a substitute for an operation when a tumour can actually be removed, and it is not offered with the expectation of clearing widespread disease. Cure in neuroendocrine tumours usually comes from complete surgical removal of localised disease. Ask your team directly what the goal of a proposed course is, in plain words, and what would count as it working.
What does CION do for pancreatic neuroendocrine tumours, and what happens at the first visit?
Start with a free 45-minute consultation at any of our 35+ centres across Telangana and Andhra Pradesh. Bring the pathology report and the scan discs rather than only the printed summaries. We read them with you, say whether the tumour is well differentiated, what its grade means and how it has behaved so far, and then say plainly whether PRRT is a realistic question for you or a distraction from a better option. Your case goes to a tumour board rather than resting on one opinion. Systemic therapy for neuroendocrine tumours, imaging and blood monitoring, nutrition and enzyme support, pain and psycho-oncology care and long-term follow-up are delivered by CION. Receptor imaging, PRRT itself, endoscopic procedures and any operation are coordinated with partner centres and may be billed there. You leave with the sequence written down and a clear split of who bills for what. Call 1800 202 8726 to book.
Medical disclaimer: This page explains what peptide receptor radionuclide therapy (PRRT) is, which pancreatic neuroendocrine tumours it is considered for and how the referral is organised, and is reviewed by a CION medical oncologist with reference to NCCN guidance on neuroendocrine tumours and the WHO classification. It is general information and not a substitute for an individual specialist opinion; whether PRRT is appropriate for you depends on your own histology, receptor imaging, kidney function and prior treatment, and must be decided with your treating team. Assessment and tumour-board planning, pathology review, systemic therapy for neuroendocrine tumours, radiation and SBRT where relevant, pancreatic-protocol CT and MRI/MRCP, chromogranin, CA 19-9 and blood monitoring, genetic counselling, nutrition and pancreatic enzyme (PERT) support, pain and psycho-oncology care and survivorship follow-up are delivered by CION. PRRT itself, DOTATATE PET and PET-CT, endoscopic ultrasound and biopsy, ERCP and biliary or duodenal stenting, coeliac plexus block and every pancreatic operation are coordinated with specialist nuclear medicine, imaging, hepatobiliary, gastroenterology and endoscopy partner centres and may be billed there.